Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Pentobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentobarbital SCHEMBL735353 | 1.00 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL24966 | 1.00 | CYP3A4 (1.00) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL26057 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL4207760 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL7639355 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL1256614 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL3695587 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL26056 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL3245534 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 | |
| Pentobarbital SCHEMBL30173355 | 0.98 | CYP3A4 (0.96) | CYP3A4ALDH1A1KDM4EGABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250144158-A1 | SLEEP IMPROVEMENT METHOD USING LIMOSILACTOBACILLUS REUTERI STRAIN LM1063 | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-05-08 | — | — | US | disclosed |
| CN-119546319-A | Composition for improving sleep or maintaining deep sleep comprising lactobacillus reuteri LM1063 strain as an active ingredient and use thereof | 乐土美森有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024195982-A2 | COMPOSITION FOR IMPROVING SLEEP OR MAINTAINING SOUND SLEEP COMPRISING LIMOSILACTOBACILLUS REUTERI LM1063 STRAIN AS ACTIVE INGREDIENT, AND USE THEREOF | 주식회사 락토메이슨 | 2024-09-26 | — | — | WO | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-0064445-A1 | N-substituted 2,4-dialkoxybenzene sulfon amides | CHOAY S.A. (FR) | 1982-11-10 | — | — | EP | disclosed |
| EP-0064006-A1 | Substituted 2,4-dialkoxybenzenesulfonyl chlorides | CHOAY S.A. (FR) | 1982-11-03 | — | — | EP | disclosed |
| US-4060637-A | 5-BROMO-N-(N,N'-DIALKYLAMINOALKYL)-O-CRESOTAMIDES | PIERRE FABRE SA (FR) | 1977-11-29 | — | — | US | disclosed |
| US-4048316-A | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning | PENN NATHAR W | 1977-09-13 | — | — | US | disclosed |
| US-4029808-A | Thienyl phenyl O-(aminoalkyl)-ketone oxime and furyl phenyl O-(aminoalkyl)-ketone oxime coronary vasodilators | C.E.R.P.H.A. A FRENCH SOCIETY ORGANISED UNDER THE LAWS OF FRANCE (FR) | 1977-06-14 | — | — | US | disclosed |
| US-3969529-A | Phenoxyacetic acid derivatives as diuretic agents | C.E.R.P.H.A. (FR) | 1976-07-13 | — | — | US | disclosed |
| US-3958002-A | ADMINISTERING | PIERRE FABRE S.A. (FR) | 1976-05-18 | — | — | US | disclosed |
| US-3951979-A | HYPOTENSIVE, ANTIEMETIC, ANTITUSSIVE | MAUVERNARY ROLAND YVES | 1976-04-20 | — | — | US | disclosed |
| US-3941878-A | ASPIRIN, A CRESOTAMIDE | PIERRE FABRE S.A. (FR) | 1976-03-02 | — | — | US | disclosed |
| US-3940490-A | N-ALKYL-5-BROMO-ORTHO-CRESOTAMIDES, ANTICONVULSANT | PIERRE FABRE S.A. (FR) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GABRB3 4269/4885GABRA2 3816/4885GABRB2 4207/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GABRB3 4269/4885GABRA2 3816/4885GABRB2 4207/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GABRB3 4269/4885GABRA2 3816/4885GABRB2 4207/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GABRB3 3591/4885GABRA2 1997/4885GABRB2 3410/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | GABRB3 3575/4885GABRA2 2590/4885GABRB2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.